Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-11-21 00:00:00+00:00 | ABBV | J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant | Johnson & Johnson JNJ announced that it submitted a supplemental biologics license application (sBLA) seeking approval for the expanded use of its cancer drug, Rybrevant (amivantamab-vmjw).
The sBLA seeks Rybrevant's approval in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of patients wi... |
2023-11-21 00:00:00+00:00 | ABBV | Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views? | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Before we discuss the reliability of brokerage recommendations... |
2023-11-21 00:00:00+00:00 | ABBV | ABBV vs. LLY: Which Stock Should Value Investors Buy Now? | Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunit... |
2023-11-20 00:00:00+00:00 | ABBV | Drugmakers agree with UK govt on renewed revenue claw-back scheme | By Ludwig Burger
Nov 20 (Reuters) - The pharmaceutical industry has agreed terms with the British government to renew a medicines access scheme that requires drugmakers to pay part of their drug revenue to the government.
The Association of the British Pharmaceutical Industry (ABPI) said in a statement on Monday that t... |
2023-11-20 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-16 00:00:00+00:00 | ABBV | Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar? | The SPDR S&P Dividend ETF (SDY) was launched on 11/08/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $19.95 billion, making it one of the larg... |
2023-11-16 00:00:00+00:00 | ABBV | AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? | AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. With results like those, you ... |
2023-11-16 00:00:00+00:00 | ABBV | AbbVie Says Ubrelvy Reduced Development Of Headache If Given At Prodrome Phase Of Migraine Attack | (RTTNews) - AbbVie (ABBV) Thursday said results from the Phase 3 PRODROME study showed that its approved drug Ubrelvy to treat migraine headaches, given during the prodrome phase of migraine attack, significantly reduced the likelihood of development of headache.
The prodrome is the earliest of four phases of a migrain... |
2023-11-15 00:00:00+00:00 | ABBV | iShares Russell 1000 Growth ETF Experiences Big Inflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $847.1 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 263,200,0... |
2023-11-15 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-14 00:00:00+00:00 | ABBV | At $100 Does Merck Stock Have Room For Growth? | Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth, as discussed below. The company reported revenue of $16.0 billion and adjusted profit of $2.13 per share compared to the consensus estimates of $15.3 bi... |
2023-11-14 00:00:00+00:00 | ABBV | 7 Dividend Stocks Every Investor Should Own to Survive a Market Crash | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There are many ways to make money on Wall Street. One of the best proven strategies is buying and holding dividend stocks for long-term wealth creation.
Countless studies prove the superiority of income-generating stocks. The asset managers at Hartford Fund... |
2023-11-14 00:00:00+00:00 | ABBV | Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie | For Immediate Release
Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, J&J JNJ and AbbVie ABBV.
Industry: Big Pharma
Link: https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes
The third-quarter earnings season has just... |
2023-11-14 00:00:00+00:00 | ABBV | 2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade | There are no absolutely surefire ways to make big profits as an investor, but it's hard to do better than dividend-paying stocks. Businesses that commit to sharing a portion of their profits with their investors tend to outperform businesses that don't, and by a wide margin.
Over the 50-year period from 1973 through 20... |
2023-11-14 00:00:00+00:00 | ABBV | 3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. It's a great idea to include a bit of both in your portfolio to support performance through any market environment. And there's on... |
2023-11-13 00:00:00+00:00 | ABBV | 4 Large Drug Stocks Likely to Sail Through Industry Woes | The third-quarter earnings season has just concluded for the drug and biotech sector. The performance of the large drugmakers was rather lukewarm, with most posting mixed results.
Higher tax rates due to changes in global tax regulations, concerns around the economy and inflation, regular pipeline setbacks and the slo... |
2023-11-13 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-13 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley | For Immediate Release
Chicago, IL – November 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Chevro... |
2023-11-13 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned -6.3% over the past month versus the Zacks S&P 500 composite's +1.4% change. The Zacks Large C... |
2023-11-10 00:00:00+00:00 | ABBV | AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock? | For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought in almost $21 billion in annual sales, and the treatment helped AbbVie grow revenue and deliver dividend growth over time.... |
2023-11-10 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-10 00:00:00+00:00 | ABBV | Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 12 cents per share for third-quarter 2023, missing the Zacks Consensus Estimate of 17 cents. The company had reported adjusted earnings of 28 cents per share in the year-ago quarter.
Total revenues in the reported quarter were $113.7 million, beating the... |
2023-11-10 00:00:00+00:00 | ABBV | Top Research Reports for NVIDIA, Chevron & AbbVie | Friday, November 10, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV). These research reports have been hand-picked from the... |
2023-11-09 00:00:00+00:00 | ABBV | Deutsche Bank Initiates Coverage of Abbvie (ABBV) with Hold Recommendation | Fintel reports that on November 9, 2023, Deutsche Bank initiated coverage of Abbvie (NYSE:ABBV) with a Hold recommendation.
Analyst Price Forecast Suggests 22.48% Upside
As of October 31, 2023, the average one-year price target for Abbvie is 173.95. The forecasts range from a low of 136.35 to a high of $215.25. The ave... |
2023-11-08 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-07 00:00:00+00:00 | ABBV | EXCLUSIVE-Activist investor Elliott targets drugmaker BioMarin -sources | By Svea Herbst-Bayliss
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical BMRN.O and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter.
The hedge fund, which oversees ... |
2023-11-07 00:00:00+00:00 | ABBV | 3 Dividend Stocks That Are Perfect for Beginning Investors | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the meme trade phenomenon helped spark interest in the equities sector, passive-income providers generally offer a more solid foundation, thus warranting a closer look at dividend stocks for beginners. To be sure, these aren’t the sexiest ideas. But t... |
2023-11-06 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-06 00:00:00+00:00 | ABBV | Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now? | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the SPDR S&P Dividend ETF (SDY) is a smart beta exchange traded fund launched on 11/08/2005.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific... |
2023-11-06 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: VONG, ABBV, PEP, CRM | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Growth ETF (Symbol: VONG) where we have detected an approximate $595.0 million dollar inflow -- that's a 4.3% increase week over week in outstanding units (from 197,131... |
2023-11-05 00:00:00+00:00 | ABBV | 3 Spectacular High-Yield Dividend Stocks to Buy in November | Not all dividend stocks are in the same league. Some offer puny yields. Others, though, provide exceptionally high ones plus solid long-term growth prospects.
Three Motley Fool contributors think they've identified stocks that belong squarely in the latter group. Here's why they view drugmakers AbbVie (NYSE: ABBV), Nov... |
2023-11-04 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-03 00:00:00+00:00 | ABBV | 5 Dividend Growth Stocks With Upside To Analyst Targets | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-11-03 00:00:00+00:00 | ABBV | Is AbbVie Stock a Buy Now? | With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. To make matters worse, its share prices are down by more than 9% this year so far, badly underperforming the market. Despite the... |
2023-11-02 00:00:00+00:00 | ABBV | Cigna raises 2023 profit forecast on lower medical costs | By Khushi Mandowara
Nov 2 (Reuters) - The Cigna Group CI.N raised its full-year profit forecast on Thursday, banking on strength in its pharmacy benefit unit and lower-than-expected insurance claims, sending the company's shares up 1.2%.
Health insurers had warned of a jump in medical costs earlier this year as older a... |
2023-11-02 00:00:00+00:00 | ABBV | These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.
We know earnings results are vital, but how a company performs compared to bottom line expectations c... |
2023-11-02 00:00:00+00:00 | ABBV | Analysts See 17% Gains Ahead For HDV | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core High Dividend ETF ... |
2023-11-02 00:00:00+00:00 | ABBV | December 22nd Options Now Available For AbbVie | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the December 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 22nd contracts and identified one put and one call contract of particular interest.
The put... |
2023-11-02 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-02 00:00:00+00:00 | ABBV | 3 Dividend Stocks That Are Investor Safe Havens | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
DividendChannel.com has a list of 25 SAFE dividend stocks.
By the site’s definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they’ve never missed or lowered dividends and they have paid dividends for at least 20 y... |
2023-11-01 00:00:00+00:00 | ABBV | Pfizer Posted a Steep Loss. Is It Time to Sell? | It's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third-quarter results would be disappointing.
It turns out the warning was more than justified. Instead of the large profit investors have gotten used to, Pfizer reported a third-quarter loss of about $... |
2023-11-01 00:00:00+00:00 | ABBV | Investor patience tested as pharmaceutical stocks take a tumble | The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.
S&P 500 components Bristol Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Merck & Co., Inc. (NYSE: MRK... |
2023-11-01 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank | For Immediate Release
Chicago, IL – November 1, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Exxon Mo... |
2023-10-31 00:00:00+00:00 | ABBV | Amgen third-quarter sales rise 5%, profit up before charge | By Deena Beasley
Oct 31 (Reuters) - Amgen AMGN.O, which earlier this month acquired Horizon Therapeutics for $27.8 billion, said on Tuesday its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Amgen said it would discuss sales of Horizon's drugs on a conference call with ana... |
2023-10-31 00:00:00+00:00 | ABBV | Is AbbVie Still a Good Dividend Stock to Buy? | One thing income seekers don't want to see from the businesses they invest in is a major disruption to their incoming cash flows. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier this year.
U.S. Humira sales ... |
2023-10-31 00:00:00+00:00 | ABBV | 5 Solid Stocks to Watch That Recently Hiked Dividends | Wall Street has remained volatile over the past couple of months owing to multiple domestic and geopolitical reasons. Rising bond yield and lack of clarity over the Federal Reserve’s future course of action with its interest rate hikes have been taking a toll on stocks.
The Federal Reserve kept its benchmark policy rat... |
2023-10-31 00:00:00+00:00 | ABBV | Amgen third-quarter sales rise 5%; profit up before charge | By Deena Beasley
Oct 31 (Reuters) - Amgen AMGN.O, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Amgen said it would discuss sales of Horizon's drugs on a conference call with ana... |
2023-10-31 00:00:00+00:00 | ABBV | J&J stock down as business unit mulls talc-related bankruptcy | Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder.
Financially, a bankruptcy for that unit would make sense, so the company could avoid substantial payouts that could put a d... |
2023-10-31 00:00:00+00:00 | ABBV | Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View | Amgen AMGN reported third-quarter 2023 adjusted earnings of $4.96 per share, which beat the Zacks Consensus Estimate of $4.65. Earnings rose 6% year over year due to higher revenues, which were partially offset by higher operating costs.
Total revenues of $6.90 billion missed the Zacks Consensus Estimate of $6.96 billi... |
2023-10-31 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-31 00:00:00+00:00 | ABBV | Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors | On Oct. 13, regulators at the Food and Drug Administration (FDA) ruled that Pfizer's (NYSE: PFE) new drug for moderate to severe ulcerative colitis (UC), Velsipity, was ready for prime time. That puts the company on a collision course with AbbVie (NYSE: ABBV), the leader of the market for ulcerative colitis therapies f... |
2023-10-30 00:00:00+00:00 | ABBV | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | Launched on 03/09/2006, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by First Trust Advisors. It has amassed assets over $3.79 billion, making it one o... |
2023-10-30 00:00:00+00:00 | ABBV | Why AbbVie Stock Was a Winner on Monday | Pharmaceutical company AbbVie (NYSE: ABBV) was a cure for the investor blues on Monday. Shares of the company rose more than 2% in price on an analyst's recommendation upgrade. AbbVie stock's resulting pop topped the bellwether S&P 500 index, which managed a comparatively light 1.2% increase on the day.
Barclays upgrad... |
2023-10-30 00:00:00+00:00 | ABBV | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | Fintel reports that on October 30, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 24.75% Upside
As of October 5, 2023, the average one-year price target for Abbvie is 173.32. The forecasts range from a low of 136.35 to a high of $215.25. ... |
2023-10-30 00:00:00+00:00 | ABBV | 2 No-Brainer Dividend Stocks to Buy This Week | Dividend stocks can be consistent market-beaters. However, empirical research shows that the best dividend stocks tend to generate better-than-average returns because of their underlying value proposition -- not their potential to deliver consistent levels of passive income.
Which undervalued dividend stocks are worth ... |
2023-10-30 00:00:00+00:00 | ABBV | S&P 500 Movers: RVTY, WDC | In early trading on Monday, shares of Western Digital topped the list of the day's best performing components of the S&P 500 index, trading up 10.3%. Year to date, Western Digital registers a 36.2% gain.
And the worst performing S&P 500 component thus far on the day is Revvity trading down 17.0%. Revvity is lower by ab... |
2023-10-29 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-27 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie Q3 23 Earnings Conference Call At 9:00 AM ET | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 27, 2023, to discuss Q3 23 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie raises profit forecast after Humira, newer drugs drive results beat | Adds shares in paragraph 2
Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs.
The results and forecast lifted AbbVie's shares 2%... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increase | (RTTNews) - AbbVie (ABBV) said the company is raising adjusted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which included an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023.
AbbVie increased its ... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates | AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was e... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View | AbbVie Inc. ABBV reported adjusted earnings of $2.95 per share for third-quarter 2023, beating the Zacks Consensus Estimate of $2.86. The reported earnings also exceeded the guidance of $2.76-$2.86. However, earnings declined 19.4% year over year.
ABBV’s revenues of $13.93 billion beat the Zacks Consensus Estimate of $... |
2023-10-27 00:00:00+00:00 | ABBV | High-yield, deep-value AbbVie fell off the patent cliff and lived | Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done nothing to change its financial health, position, long-term outlook or ability to deliver value for investors. The stock discoun... |
2023-10-27 00:00:00+00:00 | ABBV | Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics | For the quarter ended September 2023, AbbVie (ABBV) reported revenue of $13.93 billion, down 6% over the same period last year. EPS came in at $2.95, compared to $3.66 in the year-ago quarter.
The reported revenue represents a surprise of +1.65% over the Zacks Consensus Estimate of $13.7 billion. With the consensus EPS... |
2023-10-27 00:00:00+00:00 | ABBV | Why AbbVie Stock Fell Today | Shares of AbbVie (NYSE: ABBV) were down 5.4% as of 2:00 p.m. ET Friday, even after the pharmaceuticals giant announced slightly better-than-expected quarterly results and raised its full-year outlook.
For its third-quarter 2023, AbbVie's revenue declined 6% year over year (down 5.8% at constant currency) to $13.93 bill... |
2023-10-27 00:00:00+00:00 | ABBV | AbbVie Enters Oversold Territory | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... |
2023-10-27 00:00:00+00:00 | ABBV | IWY, TSLA, LLY, ABBV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $111.8 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 45,150... |
2023-10-26 00:00:00+00:00 | ABBV | Pre-Market Earnings Report for October 27, 2023 : XOM, CVX, ABBV, SNY, AON, CHTR, CL, PSX, IMO, XEL, LYB, TROW | The following companies are expected to report earnings prior to market open on 10/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2023. The oil company's consensus earnings per share forecast from the 9 ... |
2023-10-26 00:00:00+00:00 | ABBV | Lilly's bowel disease drug gets US FDA nod for treatment in adults | Adds details about the approval and launch in paragraphs 2-7
Oct 26 (Reuters) - Eli Lilly and Co LLY.N said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease.
The drug, which will be availa... |
2023-10-26 00:00:00+00:00 | ABBV | Invest in Dividend Aristocrat Stocks with the NOBL ETF | A Dividend Aristocrat is a company in the S&P 500 (SPX) that not only pays a dividend but has also increased the size of its dividend payout for at least 25 years in a row. These are the types of prudent companies that care about shareholder returns that you want to invest in for the long term, and thanks to the ProSha... |
2023-10-26 00:00:00+00:00 | ABBV | Why Earnings Season Could Be Great for AbbVie (ABBV) | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV, may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of lat... |
2023-10-26 00:00:00+00:00 | ABBV | Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond | While equity markets this year have recovered some of ground lost from the plunge of 2022, plenty of companies are still struggling. Some of them, though, clearly have the tools to rebound eventually and deliver solid returns to patient investors. Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes ... |
2023-10-26 00:00:00+00:00 | ABBV | Notable Thursday Option Activity: ABBV, ANET, WDC | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 26,502 contracts have traded so far, representing approximately 2.7 million underlying shares. That amounts to about 61.9% of ABBV's average daily trading volume over the p... |
2023-10-25 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-25 00:00:00+00:00 | ABBV | USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day | For Immediate Release
Chicago, IL – October 25, 2023 – Zacks Equity Research shares USA Compression Partners USAC as the Bull of the Day and Disney DIS as the Bear of the Day. In addition, Zacks Equity Research provides analysis on AbbVie ABBV, Amgen AMGN and Gilead Sciences GILD.
Here is a synopsis of all five stocks.... |
2023-10-24 00:00:00+00:00 | ABBV | VTV: A Must-Watch ETF for Value Investors | Value investing may not sound as exciting as investing in the next hot growth stock, but it’s a time-honored investing style that some of the most renowned investors of all time have used to generate tremendous returns over the years. In an uncertain market environment like the current one, investing in a well-establis... |
2023-10-24 00:00:00+00:00 | ABBV | Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline | Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor th... |
2023-10-24 00:00:00+00:00 | ABBV | 3 Biotech Stocks With Decent Dividend for a Steady Return | The Zacks Biomedical and Genetics industry continues to grapple with issues like unfavorable foreign currency fluctuations that affect premium growth. Also, volatile global equity markets and low bond yields put enormous pressure on the insurer’s capital position. Amid volatile market conditions, companies with an impr... |
2023-10-24 00:00:00+00:00 | ABBV | Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508).
The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus p... |
2023-10-23 00:00:00+00:00 | ABBV | AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know | In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw an increase of 0.27%.
The the stock of drugmaker has fallen by 4.26% in... |
2023-10-23 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-23 00:00:00+00:00 | ABBV | Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Big Tech Earnings | December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while market participants geared up for earnings reports from some of the biggest tech heavyweights as well as the releas... |
2023-10-23 00:00:00+00:00 | ABBV | AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards? | AbbVie ABBV will report third-quarter 2023 results on Oct 27, before market open. In the last reported quarter, the company delivered an earnings surprise of 4.30%.
Factors to Consider
AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth ... |
2023-10-20 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-20 00:00:00+00:00 | ABBV | Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline | AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor t... |
2023-10-20 00:00:00+00:00 | ABBV | 7 Dividend Stocks to Buy and Hold Forever and Ever | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Recently, investors searching for dividend stocks to buy have seen more opportunity.
Some looking for income over a longer term horizon have flooded into the bond market. Yields there are rising, and some, like treasury bonds, are nearly risk free. That has... |
2023-10-20 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific | For Immediate Release
Chicago, IL – October 20, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. A... |
2023-10-19 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: IWY, TSLA, LLY, ABBV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $431.9 million dollar inflow -- that's a 6.5% increase week over week in outstanding units (from 42,400... |
2023-10-19 00:00:00+00:00 | ABBV | 7 Dividend Aristocrats to Batten Down the Hatches | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 index which consistently raises their dividends for at least t... |
2023-10-19 00:00:00+00:00 | ABBV | Is AbbVie Stock Too Pricey to Touch Right Now? | For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. Why is the market pricing a business, which is barely expecting much growth over the next couple of years, so expensively? The market's expectati... |
2023-10-19 00:00:00+00:00 | ABBV | Is Johnson & Johnson Still a Good Dividend Stock to Buy? | It's been a transformational year for Johnson & Johnson (NYSE: JNJ). This August, the company spun off its consumer health division into a new company called Kenvue (NYSE: KVUE).
Now that Kenvue sells Listerine, Q-tips, and Tylenol, investors are concerned that the steady dividend raises Johnson & Johnson, or J&J, is f... |
2023-10-19 00:00:00+00:00 | ABBV | Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | A smart beta exchange traded fund, the Invesco Pharmaceuticals ETF (PJP) debuted on 06/23/2005, and offers broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a strategy created to reflect the... |
2023-10-18 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-10-18 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -2.8%, compared to the Zacks S&P 500 composite's -1.... |
2023-10-17 00:00:00+00:00 | ABBV | Takeda Settles Tax Dispute With Irish Revenue Commissioners Over Break Fee Received By Shire | (RTTNews) - Takeda (TAK) said it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for 130 million euros, resulting in a tax expense reduction of about JPY 63 billion for Takeda.
On November... |
2023-10-17 00:00:00+00:00 | ABBV | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off | Industries with endless demand are great places to find dividend stocks. Healthcare might be the best example of this. No matter how much technology changes, the need to prevent and treat disease will never disappear. Sure, new treatments and solutions can change the game anytime, but the best players are the companies... |
2023-10-17 00:00:00+00:00 | ABBV | AbbVie's DLBCL Drug EPKINLY, Crohn's Disease Drug RINVOQ Get Health Canada Approval | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn's Disease.
EPKINLY has received the ... |
2023-10-17 00:00:00+00:00 | ABBV | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect... |
2023-10-16 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why | In the latest market close, AbbVie (ABBV) reached $147.23, with a -0.49% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 1.06%. Meanwhile, the Dow experienced a rise of 0.93%, and the technology-dominated Nasdaq saw an increase of 1.2%.
The drugmaker's stock has dropp... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.